Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Microbia Inc.

This article was originally published in Start Up

Executive Summary

Microbia Inc. has amassed a large patent portfolio covering novel targets for rendering fungi harmless, disrupting communities of bacteria, and for harnessing these organisms to the task of manufacturing useful products. Well-armed with $59 million in funding and the chemistry skills to turn biological insights into weapons against infectious diseases, Microbia hopes to create new antimicrobial drugs that work in fundamentally different ways than the drugs that are available today.

You may also be interested in...



Ironwood Pharmaceuticals: Independent for the Long Haul

Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.

Ironwood Pharmaceuticals: Independent for the Long Haul

Ironwood Pharmaceuticals has yet to get a drug approved, yet it shares with a handful of R&D companies an increasingly implausible aspiration to become the next successful, independent, pharmaceutical growth story. Thanks to a corporate culture that values strategic thinking and a financial structure that puts change-of-control decisions in the hands of long-term shareholders, it may be uniquely positioned to achieve that goal.

Hospital-Based Infections

Physicians and hospitals are concerned about the problem of hospital-acquired infections, as is the US Centers for Disease Control, which has launched a campaign to prevent antimicrobial resistance in health care settings. Start-ups believe they can help, with effective and rapid tests for infectious disease and narrow spectrum antimicrobials targeted to specific pathogens. buhed ehnwhihOntros sion, acarel

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel